The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign In20/20 BioLabs (Nasdaq: AIDX) has announced an exclusive U.S. technology license agreement with ROKIT Healthcare Inc. to advance its diagnostic capabilities. Under the deal, the company will integrate sophisticated Chronic Kidney Disease (CKD) prediction technology into its flagship OneTest for Longevity program. This technology utilizes inflammatory biomarker tracking to optimize patient responses to 3D bio-printed therapies. By leveraging AI-powered blood tests, the partnership aims to improve the early detection of chronic diseases and enhance regenerative health outcomes. This strategic move expands AIDX's product portfolio within the high-growth longevity market. Investors view this expansion into advanced diagnostics as a positive development for the biotech firm's market positioning and long-term growth potential.